| First Author | Hecht I | Year | 2018 |
| Journal | J Immunol | Volume | 200 |
| Issue | 6 | Pages | 2025-2037 |
| PubMed ID | 29431694 | Mgi Jnum | J:313848 |
| Mgi Id | MGI:6121682 | Doi | 10.4049/jimmunol.1700325 |
| Citation | Hecht I, et al. (2018) ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses. J Immunol 200(6):2025-2037 |
| abstractText | The B7-like protein family members play critical immunomodulatory roles and constitute attractive targets for the development of novel therapies for human diseases. We identified Ig-like domain-containing receptor (ILDR)2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer. |
